December 10, 2015
Rhizen and Novartis enter deal for PI3K delta gamma inhibitor
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.